There’s a new entry into the weight-loss drug boom. Here’s the stock’s outlook
AstraZeneca is the latest player to enter the weight-loss drug space, a market that some analysts say could reach $100 billion by 2030. On Thursday, the biopharmaceutical company announced it had entered into a licensing agreement with Eccogene for ECC5004 , an oral glucagon-like peptide 1 receptor agonist. This drug,… Continue Reading There’s a new entry into the weight-loss drug boom. Here’s the stock’s outlook
